Baxter International Inc., through its subsidiary companies, produces and sells a wide range of healthcare products throughout the world. The company offers peritoneal dialysis and hemodialysis, along with other dialysis therapies and services. It also provides renal replacement therapies as well as other organ support therapies intended for use in intensive care units, sterile intravenous (IV) solutions and therapies, administration sets, drug reconstitution devices, parenteral nutrition therapies and infusion pumps.

Furthermore, it develops and distributes biological products and medical devices, as well as surgical hemostasis products and sealant products used in surgical procedures for tissue sealing, hemostasis, and adhesion prevention. These products are used in hospitals, dialysis centres, nursing homes, rehabilitation centres, physicians’ offices, as well as at home for patients under the supervision of physicians. In approximately 100 countries (with 19,000 employees in the US), the company sells its products through a direct sales force, through independent distributors, drug wholesalers, specialty pharmacies, and other alternate sites of distribution.

A major business unit of Baxter is Medical Products, which manufactures devices for use in the delivery of fluids and drugs to patients. In addition to intravenous (IV) solutions and administration sets, premixed drugs and drug recovery systems, IV nutrition products, infusion pumps, and inhalation anaesthetics are also available. As well as pharmacy compounding, this division offers drug formulation and packaging technology. Moreover, the Medical Products segment of Baxter is a pioneer in Renal home-based therapies, including peritoneal dialysis, and also offers other products and services for patients with end-stage kidney disease.

North America is home to a number of Baxter facilities, including its U.S. headquarters in Deerfield, Illinois, approximately 30 miles north of Chicago. The company’s operations in Canada include commercial and compounding pharmacy operations and manufacturing facilities. With over a dozen commercial, manufacturing, and research facilities in Europe, the Middle East, and Africa, Baxter also has significant presence in these regions, and Baxter’s Latin America region includes manufacturing and distribution as well as renal care facilities in several countries.


The PRISMAX system provides an individualized and effective way for critically ill patients in the intensive care unit (ICU) to receive their treatment. Using PRISMAX, clinicians are able to meet the changing needs of their ICU, maximising therapy delivery and the quality of patient care through improved simplicity, efficiency, and accuracy. PRISMAX incorporates features that provide real-time monitoring of therapy delivery, aiming to reduce human error.

Prismax System
© Baxter

PHOENIX X36 Hemodialysis System

The PHOENIX X36 Hemodialysis Delivery System has been designed to be an intuitive and easy-to-use device. With this system, patients weighing 15 kg and over can reliably undergo high-flux and low-flux hemodialysis, hemofiltration, and ultrafiltration. As well as its easy-to-use features, including real-time Kt/V monitoring and Compensated Blood Flow, Sodium and UF profiling and a full-colour touch screen, the PHOENIX X36 System provides built-in connectivity to EMR and allows for patient prescriptions to be downloaded using the EXALIS Dialysis Management Tool.

Phoenix x36
© Baxter


Recent News

Successful completion of the inaugural shoulder arthroplasty surgeries utilizing Stryker’s Blueprint® Mixed Reality Guidance System occurred at Mayo Clinic in Minnesota and St. Joseph’s Health Care in London, Canada.

Medical Device Technologies Market is projected to increase from USD 4.20 Billion in 2022 to USD 16.32 Billion by 2030, reflecting a robust Compound Annual Growth Rate (CAGR) of 18.50% over the forecast period

Hodess Cleanroom Construction expands its cleanroom services capabilities with the acquisitions of Protocol Management Services and Clean Rooms West

Medtronic Will Invest Up to $75 Million And begin Co-Promotion For CathWorks’ FFRangio System In The U.S. Europe and Japan

Tornier Shoulder Arthroplasty Portfolio Introduced by Stryker, With New Tornier Perform Humeral System Launched in Europe